
    
      Healthy participants will either receive a single dose (participants 9 years or older) or two
      doses (participants 6 months to 8 years) of the Shz QIV. Safety in terms of serious adverse
      events, solicited injection site and systemic reactions, and unsolicited adverse events will
      be collected before and 28 days after each and any dose.
    
  